04:36 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Tedopi: Ph III Atalante 1 ongoing

An IDMC recommended continuation of the open-label, international Phase III Atalante 1 trial comparing subcutaneous Tedopi vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients will receive Tedopi every 3 weeks...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Effimune, OSE Pharma deal

Effimune and Orphan Synergy will merge to form newco OSE Immunotherapeutics. Effimune shareholders will own about 29% of the newco, and OSE will own the remainder. The deal is subject to shareholder approval from both...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Tedopi: Phase III started

Orphan Synergy Europe began the open-label, international Phase III ATALANTE 1 trial to compare subcutaneous Tedopi vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients will receive Tedopi every 3 weeks...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Tedopi: Phase IIb data

Data from a subgroup of 6 HLA-A2-positive stage IIIB/IV NSCLC patients with brain metastases in a Phase IIb trial showed that Tedopi every 3 weeks for 18 weeks followed by every 2-3 months led to...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

OSE Pharma, Rafa deal

Orphan Synergy Europe granted Rafa exclusive rights to develop and commercialize Tedopi in Israel. Rafa will be responsible for obtaining regulatory approval. OSE will receive an undisclosed upfront payment and is eligible for undisclosed development...
00:50 , Mar 27, 2015 |  BC Extra  |  Financial News

OSE Pharma raises EUR 21.1M in IPO

OSE Pharma S.A. (Euronext:OSE) raised EUR 21.1 million ($22.8 million) in an IPO through the sale of 2 million shares at EUR 10.80. The price, which was the top of its proposed range of EUR...
02:44 , Sep 19, 2014 |  BC Extra  |  Financial News

OSE Pharma plans IPO on Euronext Paris

Orphan Synergy Europe-Pharma S.A. plans an IPO on Euronext Paris by year end to fund clinical trials of its immunotherapy Tedopi. Tedopi is a combination of 10 epitopes targeting five tumor-associated antigens often found in...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Clinical News

OSE 2101 regulatory update

Orphan Synergy Europe-Pharma said FDA granted Orphan Drug designation for OSE 2101 to treat non-small cell lung cancer (NSCLC) in HLA-A2-positive patients. A Phase II trial of OSE 2101 in severe NSCLC HLA-A2-positive patients has...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Orphan Synergy Europe-Pharma cancer news

Newco Orphan Synergy Europe-Pharma made its public debut with plans to revive development of a cancer vaccine developed more than a decade ago by co-founder Emile Loria at Epimmune Inc. OSE-Pharma acquired worldwide development rights...
00:05 , Jul 14, 2012 |  BC Extra  |  Company News

OSE-Pharma debuts to resume development of EP2101

Newco Orphan Synergy Europe-Pharma (Paris, France) made its public debut with plans to revive development of a cancer vaccine initially developed more than a decade ago by co-founder Emile Loria at San Diego-based Epimmune Inc....